Document ID: chunk:federal_register_of_legislation:F2023L00203:clause:1_4
Version: federal_register_of_legislation:F2023L00203
Segment Type: clause
Provision Reference: sch 1 cl 4
Character Range: 79984–80782

4      ≤55                                                                   ≥45

    Notes to Figure 2-A
      1. Figure 2-A is based on scales proposed by: the American Thoracic Society (1993), as adapted in Tables 5-9 and 5-10 of the AMA5; and the Thoracic Society of Australia and New Zealand (Abramson, 1996).
2.     %P = percent predicted normal value.
3.     PD20 = cumulative dose of inhaled metacholine aerosol causing a 20% decrease in FEV1.
4.     * monitored twice daily before and after aerosol bronchodilator for at least 30 days during adequate treatment.
5.     % of days = proportion of days any value of FEV1 (or of peak flow rate) is less than highest repeatable FEV1 (or peak flow rate) x 0.85.
Table 2.2: WPI derived from asthma impairment score
%WPI  Asthma impairment score